-The Hindu The proposal to extend the time limit for State-level drug regulatory approvals from four to 10 years could hit the generics market In a scathing letter to the Government of India, the Indian Pharmaceutical Alliance (IPA) took issue with what it considered to be a backdoor extension for data exclusivity norms in the country. It pointed to the recent government proposal to change the four-year time limit for State-level drug...

-The Hindu While Monsanto and Indian seed companies spar, more worrying is the confused lawmaking underpinning regulation of patents Genetically Modified Organisms (GMOs) breed controversy like no other. Little wonder then that Monsanto’s much-maligned Bt cotton has spawned the mother of all intellectual property (IP) disputes in India, involving at least 15 different proceedings in various courts, government agencies and tribunals at last count. Most proceedings appear to have come at the behest...

-The Hindu The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland. Humanitarian aid organisation Médecins Sans Frontières (MSF) has warned India that the country will not remain ‘pharmacy of the developing world’ if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland. MSF Access Campaign...

-The Hindu Intellectual property accelerates innovation in certain technology sectors, but it impedes innovation in others. The biggest flaw of the new policy is that it does not acknowledge this. Intellectual property (IP) regimes suffer a classic paradox. While they attempt to encourage innovation and creativity, they have themselves been shielded from innovation experimentation. For some years now, India has been attempting to break this mould and craft a regime to suit...

-The Indian Express Government privileges the private over the public, preferring trade to health In a dramatic development, US industry groups recently claimed the Indian government offered them a “private” assurance that compulsory licences will not be issued, save in emergencies and for non-commercial purposes. Needless to state, such an assurance flies in the face of the Patents Act and the public health safeguards enshrined in it. Illustratively, Section 84 mandates that...